{"organizations": [], "uuid": "b9726a1ac66397889f00d77a36c7061b559916e3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-advaxis-submits-conditional-maa-fo/brief-advaxis-submits-conditional-maa-for-second-line-metastatic-cervical-cancer-treatment-in-european-union-idUSFWN1Q30ZZ", "country": "US", "domain_rank": 408, "title": "Advaxis Submits Conditional MAA For Second-Line Metastatic Cervical Cancer Treatment In European Union", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.218, "site_type": "news", "published": "2018-02-13T21:44:00.000+02:00", "replies_count": 0, "uuid": "b9726a1ac66397889f00d77a36c7061b559916e3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-advaxis-submits-conditional-maa-fo/brief-advaxis-submits-conditional-maa-for-second-line-metastatic-cervical-cancer-treatment-in-european-union-idUSFWN1Q30ZZ", "ord_in_thread": 0, "title": "Advaxis Submits Conditional MAA For Second-Line Metastatic Cervical Cancer Treatment In European Union", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "european union", "sentiment": "none"}], "organizations": [{"name": "advaxis inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Advaxis Inc:\n* ADVAXIS SUBMITS CONDITIONAL MARKETING AUTHORIZATION APPLICATION FOR AXALIMOGENE FILOLISBAC FOR THE SECOND-LINE TREATMENT OF METASTATIC CERVICAL CANCER IN EUROPEAN UNION\n* ADVAXIS INC - COMPANY WILL CONTINUE ASSESSING PARTNERSHIP OPPORTUNITIES FOR POTENTIAL COMMERCIALIZATION OF AXALIMOGENE FILOLISBAC IN EUROPE\n* ADVAXIS- DECIDED TO ALIGN, SIMPLIFY STRATEGY BY USING AXALIMOGENE FILOLISBAC EXCLUSIVELY IN ALL ONGOING AND PLANNED HPV-RELATED CANCER CLINICAL TRIALS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T21:44:00.000+02:00", "crawled": "2018-02-14T12:18:13.010+02:00", "highlightTitle": ""}